Delphi consensus guidelines for the use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy for the diagnosis of dementia and mild cognitive impairment with Lewy bodies

Donaghy P. C., Greenfinch G., Petrides G., Kane J., Verberne H. J., Taylor J., ...Daha Fazla

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, cilt.18, sa.1, 2026 (ESCI, Scopus) identifier identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 18 Sayı: 1
  • Basım Tarihi: 2026
  • Doi Numarası: 10.1002/dad2.70296
  • Dergi Adı: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, Directory of Open Access Journals
  • Anahtar Kelimeler: dementia with Lewy bodies, imaging, ioflupane, metaiodobenzylguanidine, mild cognitive impairment with Lewy bodies
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Evet

Özet

INTRODUCTION: The aim of this Delphi process was to develop consensus guidelines to support the effective use of striatal dopaminergic imaging and cardiac metaiodobenzylguanidine (MIBG) scintigraphy in the diagnosis of dementia with Lewy bodies and mild cognitive impairment with Lewy bodies. METHODS: A Delphi consensus panel of 37 international experts independently indicated their agreement or disagreement with statements on indications for the use of these biomarkers and clinical situations in which each biomarker should and should not be used. Statements were accepted if they reached > 80% agreement. RESULTS: Overall, 36/70 statements (51%) were accepted in Round 1, and 19/37 (51%) were accepted in Round 2. DISCUSSION: The Delphi consensus process has developed freely available guidelines outlining clinical situations in which striatal dopaminergic imaging and cardiac MIBG scintigraphy may be useful and considerations for their use, including the effect of specific comorbidities and medications on each of the biomarkers.